Byrne Asset Management LLC Has $680,000 Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

Byrne Asset Management LLC decreased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 11.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,998 shares of the medical instruments supplier’s stock after selling 382 shares during the quarter. Byrne Asset Management LLC’s holdings in Becton, Dickinson and Company were worth $680,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Livelsberger Financial Advisory acquired a new stake in shares of Becton, Dickinson and Company in the third quarter valued at about $26,000. Ashton Thomas Securities LLC bought a new stake in Becton, Dickinson and Company during the 3rd quarter valued at approximately $33,000. Tompkins Financial Corp increased its position in Becton, Dickinson and Company by 44.2% in the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 46 shares during the period. Sound Income Strategies LLC lifted its holdings in shares of Becton, Dickinson and Company by 35.8% during the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 44 shares during the last quarter. Finally, Kennebec Savings Bank bought a new stake in shares of Becton, Dickinson and Company in the third quarter valued at approximately $46,000. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Up 1.3 %

Shares of Becton, Dickinson and Company stock opened at $230.22 on Friday. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $251.99. The stock has a market capitalization of $66.77 billion, a P/E ratio of 38.76, a price-to-earnings-growth ratio of 1.80 and a beta of 0.40. The company has a 50-day simple moving average of $231.90 and a 200 day simple moving average of $234.05. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, topping the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. Research analysts expect that Becton, Dickinson and Company will post 14.41 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be paid a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a yield of 1.81%. The ex-dividend date is Monday, March 10th. Becton, Dickinson and Company’s dividend payout ratio is currently 70.03%.

Becton, Dickinson and Company declared that its board has initiated a stock buyback program on Tuesday, January 28th that authorizes the company to buyback 10,000,000 shares. This buyback authorization authorizes the medical instruments supplier to purchase shares of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s management believes its shares are undervalued.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on BDX shares. StockNews.com lowered shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Piper Sandler lifted their target price on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 28th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, Becton, Dickinson and Company currently has a consensus rating of “Moderate Buy” and an average target price of $283.00.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP David Shan sold 500 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total transaction of $120,000.00. Following the transaction, the executive vice president now directly owns 5,741 shares in the company, valued at approximately $1,377,840. This represents a 8.01 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Michael David Garrison sold 597 shares of Becton, Dickinson and Company stock in a transaction that occurred on Friday, January 17th. The stock was sold at an average price of $236.51, for a total transaction of $141,196.47. Following the sale, the executive vice president now owns 5,544 shares of the company’s stock, valued at approximately $1,311,211.44. This represents a 9.72 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 9,844 shares of company stock valued at $2,210,716 in the last 90 days. 0.36% of the stock is currently owned by insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.